Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
  • Patent number: 10307452
    Abstract: A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil; lemon oil; grapefruit oil; tangerine oil; mandarin oil; lime oil; bergamot oil; petitgrain essential oil; and other citrus oils; meadowfoam seed oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; chlorhexidine gluconate; ginger oil; lavender oil; peppermint oil; spearmint oil; aloe oil; one or more terpenes and/or terpenoids; and a preservative, such as benzalkonium chloride and vitamin E.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: June 4, 2019
    Assignee: GLOBAL LIFE TECHNOLOGIES CORP.
    Inventor: John A. Willimann
  • Patent number: 10258565
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 16, 2019
    Assignees: ABRAXIS BIOSCIENCE, LLC, MERCATOR MEDSYSTEMS, INC.
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 10207988
    Abstract: The technology described herein relates to methods of inducing cell death. The technology described herein further relates to treating conditions including cancers and autoimmune diseases comprising administering inhibitors of double strand break repair. Also described herein are inhibitors of double strand break repair and methods of screening for such inhibitors.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 19, 2019
    Assignee: THE JACKSON LABORATORY
    Inventors: Kevin David Mills, Muneer Gulamhusien Hasham, Caroline Gardner McPhee
  • Patent number: 10201533
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, Yonglian Zhang, Sherman Tim Waddell, John M. Sanders, Thomas H. Graham, Hong Li
  • Patent number: 10166190
    Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: January 1, 2019
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventors: Nikolaj Skak, Per Holm
  • Patent number: 10143682
    Abstract: A medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: December 4, 2018
    Assignee: KOUSHI YAMAGUCHI
    Inventor: Koushi Yamaguchi
  • Patent number: 10123996
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: November 13, 2018
    Assignee: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 10039839
    Abstract: The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: August 7, 2018
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory Lawrence Verdine, Matthew James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
  • Patent number: 9987260
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: June 5, 2018
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Patent number: 9974796
    Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: May 22, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjay A. Desai, Ajay D. Pillai
  • Patent number: 9957266
    Abstract: The present invention relates to compounds that may be used for binding and imaging tau aggregates and related beta-sheet aggregates including, for example, beta-amyloid aggregates or alpha-synuclein aggregates.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: May 1, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Henner Knust, Matthias Koerner, Dieter Muri
  • Patent number: 9918968
    Abstract: The invention provides for treatment of cancers using a rapamycin analog, optionally including bortezomib. In particular, the invention addresses the treatment of bortezomib-resistant cancers using seco-rapamycin and optionally a second proteasome inhibitor. This invention relates to oncology and medicine, and more particularly to treatment of cancer. In particular, rapamycin analogs such as seco-rapamycin may be used advantageously to target the proteasome in cancer cells, optionally in conjunction with proteasome inhibitors such as bortezomib.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: March 20, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria E. Gaczynska, Pawel A. Osmulski
  • Patent number: 9920377
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: March 20, 2018
    Assignee: SUTTER WEST BAY HOSPITALS
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • Patent number: 9884013
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 6, 2018
    Assignees: Abraxis BioScience, LLC, Mercator MedSystems, Inc.
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 9855253
    Abstract: The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or the genus Candida, and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus Cryptococcus or the genus Candida, the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 2, 2018
    Assignee: INTRON BIOTECHNOLOGY CO., LTD.
    Inventors: Yong Sun Bahn, Hyo Jeong Kwon, Yeo Joon Yoon, Yeon Hee Ban
  • Patent number: 9855252
    Abstract: A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: January 2, 2018
    Assignee: PALVELLA THERAPEUTICS, LLC
    Inventors: Roger Louis Kaspar, Robyn Patricia Hickerson
  • Patent number: 9844597
    Abstract: The present invention provides compositions, and related kits and methods, for formation of hydrogels. The compositions comprise one or more chemically crosslinkable agents dissolved in an aqueous solution to form a precursor solution. The chemically crosslinkable agents useful in the present invention are selected from polymers modified with a molecule selected from acrylate, maleimide, vinylsulfone, N-hydroxysuccinimide, aldehyde, ketone, carbodiimide, carbonate, iodoacetyl, mercaptonicotinamide, quinone, thiol, amine, and combinations thereof. The precursor solution is characterized as being in an aqueous form at a non-physiologic physical-chemical condition and undergoing gelation when in contact with another fluid or body at a physiologic physical-chemical condition.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: December 19, 2017
    Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Ying Chau, Yu Yu, Jieying Zhong
  • Patent number: 9840515
    Abstract: Compounds according to Formula (I), are potent inhibitors of protein kinase D (pan-PKD) activity. PKD controls key signaling cascades in cells, affecting cell proliferation, gene transcription, and protein trafficking. Accordingly, pharmaceutically acceptable compositions of the inventive compounds are candidate therapeutics for pathological conditions conditioned by changes in PKD activity.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 12, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Qiming Jane Wang
  • Patent number: 9815859
    Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A. M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
  • Patent number: 9789141
    Abstract: This invention relates to use of probiotics, particularly P acidilactici and S boulardii, for use in conjunction with steroids and other immune suppressor agents to ameliorate symptoms of autoimmune diseases, especially disease symptoms arising from the body's production of antibodies against autologous blood cells. The practice of the invention sustains ameliorative response associated with immune suppressor agents while lowering the amount of immune suppressor agents required for treatment.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: October 17, 2017
    Assignee: IMAGILIN TECHNOLOGY, LLC
    Inventors: Jhy-Jhu Lin, Gen Kato, Takuo Ishida
  • Patent number: 9765082
    Abstract: A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-193° C. determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90<10 ?m. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 ?m, preferably 1 to 6 ?m, more preferably 1.5 to 5 ?m.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: September 19, 2017
    Assignee: EUTICALS SPA
    Inventors: Paride Grisenti, Maria Argese, Roberto Scrocchi, Alessandro Livieri, Giuseppe Guazzi
  • Patent number: 9757365
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: September 12, 2017
    Assignee: Glenmark Specialty S.A.
    Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Patent number: 9730918
    Abstract: The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: August 15, 2017
    Assignee: Plexxikon Inc.
    Inventors: Gideon Bollag, Klaus-Peter Hirth, Prabha N. Ibrahim, Paul Lin, Brian West
  • Patent number: 9717721
    Abstract: Aryl-quinolin derivatives for use in inhibiting vasculogenic mimicry, treating diseases characterized by abnormal vascular morphology or function and/or by the presence of vasculogenic mimicry in a subject in need thereof are disclosed. In one embodiment of the invention, the compounds are for use in treating metastatic tumor, hyperproliferative, or angiogenic diseases. In another embodiment of the invention, the compound for use may combine an additional therapeutic agent such as anti-cancer agents, anti-inflammatory agents, anti-proliferative agents, anti-hormonal agents, or any combination thereof for use.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: August 1, 2017
    Assignee: TAIRX, INC.
    Inventors: Yi-Wen Chu, Du-Shieng Chien
  • Patent number: 9687523
    Abstract: This invention provides a method of inducing a lacrimal acinar cell in a tissue to degrade a secretory vesicle and its content protein or proteins from the trans-Golgi network (TGN) by contacting the cells with an effective amount of an agent that induces autophagy. Also provided is a method for treating a mammal suffering from defective trans-Golgi network-secretory vesicle (TGN-SV) sorting by administering to the mammal an effective amount of an agent that induces autophagy in the tissue having the defective TGN-SV.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: June 27, 2017
    Assignee: University of Southern California
    Inventor: Sarah Hamm-Alvarez
  • Patent number: 9663529
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mimi L. Quan, Zilun Hu, Cailan Wang
  • Patent number: 9663537
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 30, 2017
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • Patent number: 9616052
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 11, 2017
    Inventor: Thomas P. Dooley
  • Patent number: 9561218
    Abstract: The present invention relates to a pharmaceutical composition comprising propiverine, trospium or glycopyrrolate; and a non-anticholinergic antiemetic agent. It is also related to a pharmaceutical composition comprising a high dose of solifenacin or a pharmaceutically acceptable salts thereof; and a non-anticholinergic antiemetic agent. Pharmaceutical compositions containing high dose of nsPAChA for use for increasing the AChEI blood concentrations and for combating neurodegeneration are also described. The invention also relates to a method for inducing neuroprotection and combating neurodegeneration in a patient suffering from Alzheimer type dementia as well as to a method for increasing the blood levels of an acetyl choline esterase inhibitor (AChEI) in a human subject treated with an AChEI dose.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: February 7, 2017
    Assignee: Chase Pharmaceuticals Corporation
    Inventors: Kathleen E. Clarence-Smith, Thomas N. Chase
  • Patent number: 9555137
    Abstract: The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: January 31, 2017
    Assignees: Sloan-Kettering Institute for Cancer Research, Cornell University
    Inventors: Gabriela Chiosis, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-Dagama, Monica L. Guzman, Hongliang Zong
  • Patent number: 9550036
    Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: January 24, 2017
    Assignee: Impel NeuroPharma Inc.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
  • Patent number: 9546135
    Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 17, 2017
    Assignee: Millendo Therapeutics, Inc.
    Inventors: Stephen Warren Hunt, III, Martin Douglas Phillips, Robert Matunas, Herman Chen, Aimesther Betancourt, Charles Uzarama, Roch Thibert
  • Patent number: 9526723
    Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: December 27, 2016
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Patrick A. Singleton
  • Patent number: 9522911
    Abstract: The present invention relates to a novel crystalline acid salt of a tricyclic derivative or a hydrate thereof and a production method thereof. The crystalline acid salt or the hydrate thereof according to the present invention is stable with respect to humidity and stable with respect to hygroscopicity, and the quality control during manufacturing drugs is favorable. In addition, the crystalline acid salt or the hydrate thereof may be used in a pharmaceutical composition for preventing or treating neuropathic pain, epilepsy, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, schizophrenia, chronic and acute pain, ischemic brain injury, neuronal loss after hypoxia, trauma and nerve damage, which are medical conditions induced by PARP overactivity.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: December 20, 2016
    Assignee: JEIL PHARMACEUTICAL CO., LTD.
    Inventors: In-Hae Ye, Chun-Ho Park, Jong-Hee Choi, Dong-il Kang
  • Patent number: 9517231
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: December 13, 2016
    Inventor: Thomas P. Dooley
  • Patent number: 9511385
    Abstract: An automated apparatus and method for coating medical devices such as an intravascular stent, are disclosed in the method, a 2-D image of a stent is processed to determine (1) paths along the stent skeletal elements by which a stent secured to a rotating support element can be traversed by a dispenser head whose relative motion with respect to the support element is along the support-element axis, such that some or all of the stent skeletal elements will be traversed (2) the relative speeds of the dispenser head and support element as the dispenser head travels along the paths, and (3), and positions of the dispenser head with respect to a centerline of the stent elements as the dispenser head travels along such paths The rotational speed of the support and relative linear speed of the dispenser are controlled to achieve the desired coating thickness and coating coverage on the upper surfaces, and optionally, the side surfaces, of the stem elements.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: December 6, 2016
    Assignee: BIOSENSORS INTERNATIONAL GROUP, LTD.
    Inventors: Ivan Vecerina, Vinh Pham
  • Patent number: 9505773
    Abstract: Novel rapamycin analogues and methods for their production with FKBP and/or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: November 29, 2016
    Assignee: Isomerase Therapeutics Ltd.
    Inventors: Matthew Alan Gregory, Steven Gary Kendrew, Steven James Moss, Barrie Wilkinson
  • Patent number: 9468607
    Abstract: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: October 18, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan
  • Patent number: 9464066
    Abstract: The present application is related to deuterated compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders involving degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such deuterated compounds.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: October 11, 2016
    Assignee: Pharmatrophix, Inc.
    Inventor: Damodara Gopal
  • Patent number: 9464103
    Abstract: Disclosed herein are compounds of Formula (I), wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: October 11, 2016
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Dmitri Pissarnitski, Zhiqiang Zhao
  • Patent number: 9446030
    Abstract: The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and/or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and/or panic episode.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 20, 2016
    Inventor: Thomas P. Dooley
  • Patent number: 9427433
    Abstract: Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure, restoring glucose tolerance and/or preventing glucose intolerance and/or maintaining glucose homeostasis and/or inducing or enhancing weight loss, treating dyslipidemia, treating hypertestosteronism or hyperandrogenism, and/or treating type 2 diabetes in an individual in need thereof are provided. These involve compositions that inhibit expression of interferon-gamma (IFN-?) or a downstream IFN-?-stimulated gene, which is preferably a macrolide immunosuppressant compound.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: August 30, 2016
    Assignee: Queen's University at Kingston
    Inventors: Ahmad J. H. Albaghdadi, Frederick W. K. Kan
  • Patent number: 9415018
    Abstract: The present invention relates to methods for improving muscle strength and treating muscular dystrophy.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: August 16, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Samuel A. Wickline, Gregory M. Lanza
  • Patent number: 9364507
    Abstract: This invention relates to use of probiotics, particularly P acidilactici and S boulardii, for use in conjunction with steroids and other immune suppressor agents to ameliorate symptoms of autoimmune diseases, especially disease symptoms arising from the body's production of antibodies against autologous blood cells. The practice of the invention sustains ameliorative response associated with immune suppressor agents while lowering the amount of immune suppressor agents required for treatment.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: June 14, 2016
    Assignee: IMAGILIN TECHNOLOGY, LLC
    Inventors: Jhy-Jhu Lin, Gen Kato, Takuo Ishida
  • Patent number: 9365582
    Abstract: Inhibitors of HCV replication of formula (I) and the salts and stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 is C1-6alkyl or C3-7cycloalkyl; R5 is hydrogen, halo, C1-6alkyl, hydroxy, C1-6alkoxy, polyhaloC1-6alkyl; R6 is hydrogen, C1-6alkoxy, mono- or diC1-6alkylamino; or R5 and R6 may form a 5- or 6-membered unsaturated or partially unsaturated ring, optionally comprising one or two selected from O, N and S; R7 is hydrogen; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl; R8 is C3-7cycloalkyl optionally substituted with C1-6alkyl; C1-6alkyl optionally substituted with C3-7cycloalkyl; or —NR8aR8b; R8a and R8b are C1-6alkyl, or both may form a 5- or 6-member
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: June 14, 2016
    Assignee: Janssen Sciences Ireland UC
    Inventors: Pierre Jean-Marie Raboisson, Herman Augustinus De Kock, David Craig McGowan, Lili Hu, Abdellah Tahri, Sandrine Marie Helene Vendeville, Wim Van De Vreken
  • Patent number: 9340539
    Abstract: A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X1 and X2 are each independently CRB or N; RB is H, (C1-6)alkyl, (C1-6)haloalkyl, halo.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: May 17, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Brochu, Chantal Grand-Maitre, Lee Fader, Cyrille Kuhn, Megan Bertrand-Laperle, Marc Pesant
  • Patent number: 9334283
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: May 10, 2016
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • Patent number: 9327029
    Abstract: An antimicrobial therapeutic hydrogel composition comprises a pharmaceutical and/or medical grade silver salt, and an Aloe vera gel or extract. The composition could also include stabilizing agents, a non-ionic surfactant, polyol, and hydrophilic hygroscopic polymers. The resulting product has potent antimicrobial activity against bacteria, protozoa, fungi and viruses. The antimicrobial therapeutic composition can serve as a treatment for burns and as a wound/lesion dressing that either donates or receives moisture to provide a physiologic environment for accelerated wound healing and the relief of pain.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: May 3, 2016
    Assignee: CelaCare Technologies, LLC
    Inventors: Kenneth M. Yates, Celia A Proctor, Dan H Atchley
  • Patent number: 9321782
    Abstract: The invention discloses novel 42-0-(heteroalkoxyalkyl) rapamycin compounds of formula (1) and process for preparation thereof. These compounds are useful in the treatment of hyperproliferative vascular diseases such as restenosis and atherosclerosis Wherein, R denotes 3, 4 and 5 membered 3-hydroxy heteroalkoxyalkyl compounds selected from Tetrahydrofuran-3-ol, Oxetan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-4- methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2,5-diethyl-2-methyl furan-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: April 26, 2016
    Assignee: MERIL LIFE SCIENCES PVT. LTD.
    Inventors: Dhananjay Sharad Rane, Rajnikant Gandalal Vyas, Pramod Kumar Minocha
  • Patent number: 9292660
    Abstract: Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 22, 2016
    Assignee: Caris MPI, Inc.
    Inventors: Daniel D. Von Hoff, David M. Loesch, Arlet Alarcon, Robert J. Penny, Alan Wright, Matthew J. McGinniss, Ryan P. Bender, Traci Pawlowski